Skip to content

The Association of Genetic Polymorphisms With Statin-Induced Myopathy.

Association Analysis Between Single Nucleotide Polymorphisms in Statin-Related Genes and The Incidence of Myopathy Among Statin-Treated Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00549029
Enrollment
150
Registered
2007-10-25
Start date
2007-08-31
Completion date
2008-01-31
Last updated
2007-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rhabdomyolysis, Myopathy

Keywords

muscle disorder, statins, creatine kinase

Brief summary

To observe not only the distribution of single nucleotide polymorphism in genes related with pharmacodynamic and pharmacokinetics alteration of statins but also to analyze the correlation between these SNPs and the incidence of statins-induced myopathy.

Detailed description

Statins are widely prescribed for the patients with hypercholesterolemia. Though their efficacy in preventing cardiovascular events has been shown by a large number of clinical trials, myotoxic side effects including myopathy or even more severe,rhabdomyolysis are associated with the use of statins. Because the incidence of myopathy is various among individuals,polymorphism in genes is supposed to be the main factor. Due to single nucleotide polymorphism in related genes,level of uptake, clearance and metabolism of statins can be seriously different among individuals resulting in various occurrence of myopathy. Therefore, analytical study in association between SNP of statins-related genes and the incidence of myopathy is such a critical research which can be applied into clinical fields.

Interventions

GENETICDNA

withdraw 5\ 10mL blood from vein only once during the whole design

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of Rhabdomyolysis because of prescription with statins

Exclusion criteria

* Carnitine palmityl transferase ll deficiency * McArdle disease * Myoadenylate deaminase deficiency

Design outcomes

Primary

MeasureTime frame
genotype of specific genesone day

Secondary

MeasureTime frame
single nucleotide polymorphismone day

Countries

Taiwan

Contacts

Primary ContactYen-Hui Chen, PhD
tcyhchen@ntu.edu.tw886-2-2312-3456
Backup ContactTzung-Dau Wang, PhD
tdwang@ntu.edu.tw886-2-2312-3456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026